ES2196772T3 - Compuestos amino ciclicos. - Google Patents

Compuestos amino ciclicos.

Info

Publication number
ES2196772T3
ES2196772T3 ES99906508T ES99906508T ES2196772T3 ES 2196772 T3 ES2196772 T3 ES 2196772T3 ES 99906508 T ES99906508 T ES 99906508T ES 99906508 T ES99906508 T ES 99906508T ES 2196772 T3 ES2196772 T3 ES 2196772T3
Authority
ES
Spain
Prior art keywords
group
groups
alkyl
alkoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99906508T
Other languages
English (en)
Inventor
Fumitoshi Asai
Atsuhiro Sugidachi
Toshihiko Ikeda
Haruo Iwabuchi
Yoshiaki Kuroki
Teruhiko Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Ube Corp
Original Assignee
Sankyo Co Ltd
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd, Ube Industries Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2196772T3 publication Critical patent/ES2196772T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)

Abstract

Un compuesto amino cíclico representado por la fórmula siguiente: **(Fórmula)** en la que: R1 representa un grupo fenilo que puede estar opcionalmente sustituido por al menos un sustituyente seleccionado entre el grupo que consiste en átomos de halógeno, grupos alquilo de C1-C4, grupos (alquilo de C1-C4) sustituidos con flúor, grupos alcoxi de C1-C4, grupos (alcoxi de C1-C4) sustituidos con flúor, grupos ciano y grupos nitro; R2 representa un grupo acilo alifático de C1-C8 que puede estar opcionalmente sustituido por al menos un sustituyente seleccionado entre el grupo que consiste en átomos de halógeno, grupos alcoxi de C1-C4 y grupos ciano, un grupo benzoilo que puede estar opcionalmente sustituido por al menos un sustituyente seleccionado entre el grupo que consiste en átomos de halógeno, grupos alquilo de C1-C4 y grupos alcoxi de C1-C4, o un grupo (alcoxi de C1-C4)carbonilo; y R3 representa un grupo amino cíclico saturado que tiene en total entre 2 y 8 átomos de carbono en uno o más anillos, teniendo el mayor anillo que contiene nitrógeno entre 3 y 7 átomos en el anillo, estando sustituido dicho grupo amino cíclico saturado por un grupo de fórmula -S-X-R4 en la que R4 y X son tal como se definen a continuación, estando unido dicho grupo amino cíclico saturado a través de un átomo de nitrógeno del anillo del mismo al átomo de carbono adyacente al que están unidos los sustituyentes R1 y R2, y conteniendo de forma opcional dicho grupo amino cíclico saturado un heteroátomo adicional en el anillo seleccionado entre el grupo que consiste en átomos de oxígeno, nitrógeno y azufre, R4 representa un grupo fenilo que puede estar opcionalmente sustituido por al menos un sustituyente seleccionado entre el grupo que consiste en átomos de halógeno, grupos alquilo de C1-C4, grupos alcoxi de C1-C4, grupo nitros y grupos ciano, un grupo alquilo de C1-C6 que puede estar opcionalmente sustituido por al menos un sustituyente seleccionado entre el grupo que consiste en grupos amino, grupos hidroxilo, grupos carboxilo, grupos (alcoxi de C1-C4)carbonilo, sustituyentes de fórmula -NH-A1 (en la que, A1 representa un residuo de un a-amino ácido) y sustituyentes de fórmula -CO-A2 (en la que, A2 representa un residuo de un a-amino ácido), o un grupo cicloalquilo de C3-C8, y X representa un átomo de azufre, un grupo sulfinilo o un grupo sulfonilo, y dicho grupo amino cíclico puede estar adicionalmente sustituido por un grupo de fórmula =CR5R6, en la que R5 y R6 son iguales o diferentes y cada uno de ellos representa de forma independiente un átomo de hidrógeno, un grupo alquilo de C1-C4, un grupo carboxilo, un grupo (alcoxi de C1-C4)carbonilo, un grupo carbamoilo, un grupo (alquilo de C1-C4) carbamoilo o un grupo di-(alquilo de C1-C4) carbamoilo; o una sal farmacológicamente aceptable del mismo.
ES99906508T 1998-02-27 1999-02-26 Compuestos amino ciclicos. Expired - Lifetime ES2196772T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4692198 1998-02-27

Publications (1)

Publication Number Publication Date
ES2196772T3 true ES2196772T3 (es) 2003-12-16

Family

ID=12760807

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99906508T Expired - Lifetime ES2196772T3 (es) 1998-02-27 1999-02-26 Compuestos amino ciclicos.

Country Status (23)

Country Link
US (1) US6610708B1 (es)
EP (1) EP1063230B1 (es)
KR (1) KR100567950B1 (es)
CN (1) CN100369896C (es)
AT (1) ATE238279T1 (es)
AU (1) AU737303B2 (es)
BR (1) BRPI9908319B8 (es)
CA (1) CA2322171C (es)
CZ (1) CZ300821B6 (es)
DE (1) DE69907166T2 (es)
DK (1) DK1063230T3 (es)
ES (1) ES2196772T3 (es)
HU (1) HU225741B1 (es)
ID (1) ID25589A (es)
IL (1) IL138068A (es)
MX (1) MXPA00008439A (es)
NO (1) NO317882B1 (es)
NZ (1) NZ506574A (es)
PL (1) PL200666B1 (es)
PT (1) PT1063230E (es)
RU (1) RU2203887C2 (es)
TR (1) TR200002505T2 (es)
WO (1) WO1999043648A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060108691A (ko) * 2003-11-28 2006-10-18 상꾜 가부시키가이샤 헤테로아릴고리를 갖는 고리상 아민 유도체
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
TW200720252A (en) * 2005-05-27 2007-06-01 Sankyo Co Cyclic amine derivative having substituted alkyl group
RU2312660C2 (ru) * 2005-07-25 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО ПГФА Росздрава) 4-ацетил-3-гидрокси-1-(2-гидроксиэтиламиноэтил)-5-фенил-3-пирролин-2-он, проявляющий антикоагулянтную активность
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168022A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
SG11201505283RA (en) 2013-01-09 2015-08-28 Univ Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN107921135A (zh) 2015-04-30 2018-04-17 密歇根大学董事会 噻吩并吡啶化合物的混合二硫共轭物及其用法
CN106554302A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554369A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
US12188069B2 (en) 2018-01-31 2025-01-07 The Regents Of The University Of Michigan Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds
US11642335B2 (en) * 2019-09-26 2023-05-09 Board Of Regents, The University Of Texas System Chemical synthesis of clopidogrel active metabolites and disulfide conjugate prodrugs
CN111484446A (zh) * 2020-04-02 2020-08-04 北京翼方生物科技有限责任公司 氯吡格雷代谢活性体二硫衍生物、其制备方法及医药用途
CN111848497A (zh) * 2020-07-28 2020-10-30 内蒙古医科大学 氯吡格雷活性代谢物衍生物、其前药及其制备方法与应用
CN112851570A (zh) * 2021-01-13 2021-05-28 北京沃邦医药科技有限公司 不饱和环胺半胱氨酸二硫衍生物制备方法及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555854A (en) * 1896-03-03 Brush-handle attachment
US3647796A (en) * 1968-12-23 1972-03-07 Parke Davis & Co Cyclicamino alkylaminothioacridine
FR2215948B1 (es) 1973-02-01 1976-05-14 Centre Etd Ind Pharma
FR2495156A1 (fr) * 1980-11-28 1982-06-04 Sanofi Sa Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
US4845121A (en) * 1986-06-13 1989-07-04 The Ohio State University Research Foundation Aci-reductone compounds belonging to the 6,7-disubstituted-3,4-dihydro benzopyan-2H-one class having antiaggregatory properties
JPH04334358A (ja) * 1991-05-02 1992-11-20 Ono Pharmaceut Co Ltd 縮合ベンゼンオキシ酢酸誘導体
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
WO1993014077A1 (en) * 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1994022440A1 (en) * 1993-03-29 1994-10-13 Smithkline Beecham Corporation Bicyclic compounds which inhibit platelet aggregation
ES2134284T3 (es) 1993-04-23 1999-10-01 Hoechst Ag Pirido-pirimidindionas, procedimiento para su preparacion y su empleo como medicamentos.
AU698748B2 (en) * 1993-09-17 1998-11-05 Brigham And Women's Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives

Also Published As

Publication number Publication date
CZ20003119A3 (cs) 2001-01-17
NO317882B1 (no) 2004-12-27
EP1063230A4 (en) 2001-12-12
IL138068A0 (en) 2001-10-31
WO1999043648A1 (en) 1999-09-02
ATE238279T1 (de) 2003-05-15
KR20010041367A (ko) 2001-05-15
BRPI9908319B1 (pt) 2012-01-10
CN100369896C (zh) 2008-02-20
DE69907166T2 (de) 2004-02-05
US6610708B1 (en) 2003-08-26
PL200666B1 (pl) 2009-01-30
HU225741B1 (en) 2007-07-30
NO20004279D0 (no) 2000-08-25
EP1063230B1 (en) 2003-04-23
PT1063230E (pt) 2003-07-31
NO20004279L (no) 2000-10-26
PL342573A1 (en) 2001-06-18
MXPA00008439A (es) 2002-04-24
TR200002505T2 (tr) 2000-12-21
DE69907166D1 (de) 2003-05-28
CZ300821B6 (cs) 2009-08-19
AU737303B2 (en) 2001-08-16
CN1298389A (zh) 2001-06-06
EP1063230A1 (en) 2000-12-27
ID25589A (id) 2000-10-19
KR100567950B1 (ko) 2006-04-05
DK1063230T3 (da) 2003-07-14
BRPI9908319A (pt) 2000-11-07
CA2322171A1 (en) 1999-09-02
AU2641399A (en) 1999-09-15
BRPI9908319B8 (pt) 2021-07-06
RU2203887C2 (ru) 2003-05-10
HUP0100950A3 (en) 2002-12-28
NZ506574A (en) 2003-06-30
IL138068A (en) 2005-11-20
HUP0100950A2 (hu) 2001-08-28
CA2322171C (en) 2009-10-27

Similar Documents

Publication Publication Date Title
AR056208A1 (es) Compuesto hidrazida y su uso pesticida
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
PE20040373A1 (es) Composiciones herbicidas que comprenden derivados de isoxazolina
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
CO4910135A1 (es) Derivados cetolidos 6-0 sustituidos de la eritromicina que tienen actividad bacteriana
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
SE0300956D0 (sv) Stabilisatorblandningar
CO5580747A2 (es) Derivados e intermediarios de n-adamantilmetilo como composiciones farmaceuticas y procesos para su preparacion
TW200745058A (en) MMP-13 selective inhibitors
CA2423103A1 (en) N-acylsulfonamide apoptosis promoters
CO4980859A1 (es) Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina
KR850000433A (ko) 치횐된 2-피리미디닐-1-피페라진 유도체의 제조방법
ECSP045369A (es) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
NO980856L (no) Piperazinderivater og fremgangsmÕte for fremstilling derav
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
AR043055A1 (es) Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
ES2182546T3 (es) Imidazo(1,2a)azinas sustituidas como inhibidores selectivos de la cox-2.